Manages acute pain severe enough to require an opioid analgesic. ANDA 214378, held by Epic Pharma LLC. Tapentadol Hydrochloride.
As of Nov 16, 2026, ANDA 214378 (Tapentadol Hydrochloride), held by Epic Pharma LLC, was first approved by FDA on Jan 27, 2026, with 1 approved supplement and 0 published complete response letters.
Tapentadol tablets are indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in adults. Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dose or duration, and persist over the course of therapy, reserve opioid analgesics, including tapentadol tablets for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Pediatric use information is approved for Collegium Pharmaceutical, Inc.’s NUCYNTA tablets.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 27, 2026 | Original application | Approved |
| Tapentadol HydrochlorideEQ 50MG BASE · tablet;oral | Tapentadol Hydrochloride | Rx |
| Tapentadol HydrochlorideEQ 75MG BASE · tablet;oral | Tapentadol Hydrochloride | Rx |
| Tapentadol HydrochlorideEQ 100MG BASE · tablet;oral | Tapentadol Hydrochloride | Rx |
| Jun 18, 2026 | Supplement 3REMS | Approved | None posted |
| Jan 27, 2026 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters